U.S. Markets closed

Admera Health Launches, Introduces Molecular Diagnostics Pipeline at CAP '14

SOUTH PLAINFIELD, NJ--(Marketwired - Sep 8, 2014) - Molecular diagnostics company, Admera Health, is featuring proprietary pharmacogenomics test PGxOne™ among other personalized genomic tests at CAP '14: The Pathologists' Meeting™ this week in Chicago, IL.

A GENEWIZ company, Admera Health was founded in 2014 as a spin-off of the GENEWIZ, Inc. Clinical Services business unit for the delivery of clinical genomic products and services. Focusing on personalized medicine, Admera Health aims to deliver transformative, valuable solutions for patients, physicians, payers, and clinical researchers.

"Thanks to the breakthrough of genomic technologies and rapid advancements in the understanding of the relationship between the human genome and diseases, we have a once-in-a-decade opportunity to make personalized medicine a reality," asserted Dr. Guanghui Hu, President, Admera Health. "We plan to make the most of this opportunity by optimizing the resources, expertise, and experience available to Admera Health through GENEWIZ in order to achieve our shared vision of improving patients' quality of life and the overall health of our global community."

"Our first product, PGxOne™, addresses this opportunity by using next generation sequencing and advanced bioinformatics analysis to provide comprehensive and medically actionable results for personalized patient care, thus increasing treatment efficacy and decreasing adverse drug effects," Hu stated.

Focusing on the development of cost-effective tests that fulfill unmet medical needs, the Admera Health pipeline includes cancer gene panel, OncoGxOne™, as well as non-invasive cancer testing and microbiome testing.

"More accurate diagnoses and precise treatments through molecular diagnostics offer new hope for the millions of patients battling cancer each year," said CAP President Gene N. Herbek, MD, FCAP. "As the doctors who diagnose disease and guide treatment, pathologists want to keep current on the new diagnostic procedures that can enhance patient care. CAP '14 brings together the leading experts in laboratory medicine to share the latest information to benefit patients."

To learn more about Admera Health, visit booth 105 at CAP'14 this week.

About Admera Health
Admera Health is a molecular diagnostics company focused on personalized medicine. Utilizing advanced genomic technologies and bioinformatics analysis, Admera Health delivers cost-effective clinical diagnostics spanning the continuum of care from its established, CAP-accredited laboratory. Admera Health is a GENEWIZ company.

About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, and GLP regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions. Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

About the College of American Pathologists
As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,600 laboratories and providing proficiency testing to 20,000 laboratories worldwide.